Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
1.650
-0.010 (-0.60%)
Aug 17, 2026, 11:19 AM EST
Interpace Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 36.14 | 38.73 | 46.93 | 40.04 | 31.84 | 33.12 | |
Revenue Growth | -20.48% | -17.47% | 17.21% | 25.75% | -3.86% | 2.22% |
Cost of Revenue | 13.1 | 14.6 | 17 | 14.98 | 13.61 | 14.31 |
Gross Profit | 23.04 | 24.13 | 29.93 | 25.06 | 18.23 | 18.8 |
Selling, General & Admin | 18.27 | 18.7 | 21.14 | 19.6 | 20.1 | 19.88 |
Research & Development | 0.59 | 0.64 | 0.68 | 0.64 | 0.7 | 1.49 |
Amortization of Goodwill & Intangibles | - | - | - | 0.86 | 1.27 | 3.19 |
Operating Expenses | 18.87 | 19.35 | 21.82 | 21.09 | 22.07 | 24.57 |
Operating Income | 4.18 | 4.78 | 8.11 | 3.96 | -3.84 | -5.76 |
Interest Expense | -0.04 | -0.17 | -0.66 | -1.01 | -1.01 | -1.04 |
Other Non Operating Income (Expenses) | -0.13 | -0.14 | -0.5 | -0.67 | -1.21 | -0.38 |
EBT Excluding Unusual Items | 4.01 | 4.47 | 6.95 | 2.29 | -6.06 | -7.18 |
Merger & Restructuring Charges | -0.01 | -0.7 | - | - | - | -0.9 |
Other Unusual Items | - | - | - | -0.01 | 0.22 | 0.34 |
Pretax Income | 4 | 3.77 | 6.95 | 2.28 | -5.84 | -7.74 |
Income Tax Expense | -20.86 | -21.21 | 0 | 0.02 | 0.03 | -0.71 |
Earnings From Continuing Operations | 24.86 | 24.98 | 6.95 | 2.26 | -5.87 | -7.04 |
Earnings From Discontinued Operations | -0.41 | -0.41 | -0.24 | -0.31 | -16.09 | -7.91 |
Net Income | 24.45 | 24.58 | 6.7 | 1.95 | -21.96 | -14.94 |
Preferred Dividends & Other Adjustments | - | - | 0.46 | - | - | - |
Net Income to Common | 24.45 | 24.58 | 6.24 | 1.95 | -21.96 | -14.94 |
Net Income Growth | 496.27% | 293.96% | 219.24% | - | - | - |
Shares Outstanding (Basic) | 15 | 4 | 4 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 27 | 28 | 16 | 4 | 4 | 4 |
Shares Change | 0.30% | 76.02% | 260.54% | 2.97% | 2.49% | 2.63% |
EPS (Basic) | 1.67 | 5.55 | 1.42 | 0.45 | -5.18 | -3.61 |
EPS (Diluted) | 0.89 | 0.89 | 1.39 | 0.45 | -5.18 | -3.61 |
EPS Growth | 24.12% | -36.52% | 210.60% | - | - | - |
Free Cash Flow | 4.1 | 5.48 | 3.77 | 3.32 | -8.01 | -9.07 |
Free Cash Flow Per Share | 0.15 | 0.20 | 0.24 | 0.76 | -1.89 | -2.19 |
Gross Margin | 63.75% | 62.31% | 63.77% | 62.58% | 57.26% | 56.78% |
Operating Margin | 11.55% | 12.35% | 17.28% | 9.90% | -12.06% | -17.41% |
Profit Margin | 67.64% | 63.45% | 13.29% | 4.88% | -68.97% | -45.12% |
Free Cash Flow Margin | 11.36% | 14.14% | 8.03% | 8.29% | -25.17% | -27.40% |
EBITDA | 4.65 | 5.21 | 8.41 | 4.99 | -1.28 | -0.39 |
EBITDA Margin | 12.86% | 13.45% | 17.92% | 12.46% | -4.02% | -1.18% |
D&A For EBITDA | 0.47 | 0.43 | 0.3 | 1.03 | 2.56 | 5.37 |
EBIT | 4.18 | 4.78 | 8.11 | 3.96 | -3.84 | -5.76 |
EBIT Margin | 11.55% | 12.35% | 17.28% | 9.90% | -12.06% | -17.41% |
Effective Tax Rate | - | - | 0.06% | 0.74% | - | - |